THE IMPACT OF METFORMIN USE ON RISK, PROGRESSION, AND SEVERITY OF DEMENTIA: A SYSTEMATIC REVIEW

Main Article Content

Lakachew Bekele
Sundas Kanwal
Rabia Taj
Raana Mahmood
Paula Jativa
Nicole Yañez Villacres
Aleena Shahzad

Keywords

Metformin, Dementia, Neuroprotection, Cognitive Function, Systematic Review

Abstract

This study aimed to investigate the impact of metformin use on the risk, progression, and severity of dementia, considering its potential neuroprotective effects. Through a comprehensive literature review and analysis of epidemiological studies, clinical trials, and comparative research, we synthesized evidence to evaluate the relationship between metformin therapy and dementia outcomes. Our findings revealed conflicting perspectives, with some studies suggesting a potential protective effect of metformin in reducing dementia risk, while others indicated mixed results regarding its influence on cognitive function and disease progression in diagnosed patients. Despite these discrepancies, our analysis underscores the importance of personalized approaches to metformin therapy and the need for further research, particularly large-scale, long-term randomized controlled trials, to clarify its therapeutic potential and optimize clinical practice in the context of dementia management.

Abstract 126 | Pdf Downloads 61

References

Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., Jabir, M. S., Negm, W. A., & Batiha, G. E.-S. (2024). Metformin role in Parkinson’s disease: a double-sword effect. Molecular and Cellular Biochemistry, 479(4), 975-991.
2. Avan, A., & Hachinski, V. (2023). Global, regional, and national trends of dementia incidence and risk factors, 1990–2019: a Global Burden of Disease study. Alzheimer's & Dementia, 19(4), 1281-1291.
3. Barone, E., Di Domenico, F., Perluigi, M., & Butterfield, D. A. (2021). The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 176, 16-33.
4. Cui, W., Lv, C., Geng, P., Fu, M., Zhou, W., Xiong, M., & Li, T. (2024). Novel targets and therapies of metformin in dementia: old drug, new insights. Frontiers in Pharmacology, 15, 1415740.
5. Foretz, M., Guigas, B., & Viollet, B. (2019). Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology, 15(10), 569-589.
6. Koenig, A. M., Mechanic-Hamilton, D., Xie, S. X., Combs, M. F., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017). Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Disease & Associated Disorders, 31(2), 107-113.
7. Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022). Alzheimer’s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. International journal of molecular sciences, 23(5), 2687.
8. Sanati, M., Aminyavari, S., Afshari, A. R., & Sahebkar, A. (2022). Mechanistic insight into the role of metformin in Alzheimer's disease. Life Sciences, 291, 120299.
9. Sood, A., Capuano, A. W., Wilson, R. S., Barnes, L. L., Kapasi, A., Bennett, D. A., & Arvanitakis, Z. (2024). Metformin, age-related cognitive decline, and brain pathology. Neurobiology of Aging, 133, 99-106.
10. Thorpe, C. T., Gellad, W. F., Good, C. B., Zhang, S., Zhao, X., Mor, M., & Fine, M. J. (2015). Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes care, 38(4), 588-595.
11. Wiese, L. A. K., Gibson, A., Guest, M. A., Nelson, A. R., Weaver, R., Gupta, A., Carmichael, O., Lewis, J. P., Lindauer, A., & Loi, S. (2023). Global rural health disparities in Alzheimer's disease and related dementias: State of the science. Alzheimer's & Dementia, 19(9), 4204-4225.
12. Wu, C.-Y., Shapiro, L., Ouk, M., MacIntosh, B. J., Black, S. E., Shah, B. R., & Swardfager, W. (2022). Glucose-lowering drugs, cognition, and dementia: the clinical evidence. Neuroscience & Biobehavioral Reviews, 137, 104654.
13. Xu, D., Affandi, J., Yap, T., & Reid, C. (2020). Metformin use beyond diabetes: reducing cardiovascular events in the healthy elderly. Journal of Gerontology & Geriatric Medicine, 6(058).
14. Xue, Y., & Xie, X. (2023). The association between metformin use and risk of developing severe dementia among ad patients with type 2 diabetes. Biomedicines, 11(11), 2935.
15. Koo, B. K., Kim, L. K., Lee, J. Y., & Moon, M. K. (2019). Taking metformin and cognitive function change in older patients with diabetes. Geriatrics & Gerontology International, 19(8), 755-761. https://doi.org/10.1111/ggi.13692
16. Liao, W., Xu, J., Li, B., Ruan, Y., Li, T., & Liu, J. (2022). Deciphering the roles of metformin in Alzheimer's disease: A snapshot. Frontiers in Pharmacology, 12, 728315. https://doi.org/10.3389/fphar.2021.728315
17. Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2012). Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: A population-based case-control study. Journal of the American Geriatrics Society, 60(5), 916-921. https://doi.org/10.1111/j.1532-5415.2012.03916.x
18. Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018). The therapeutic potential of metformin in neurodegenerative diseases. Frontiers in Endocrinology, 9, 400. https://doi.org/10.3389/fendo.2018.00400
19. Ji, S., Zhao, X., Zhu, R., Dong, Y., Huang, L., & Zhang, T. (2022). Metformin and the risk of dementia based on an analysis of 396,332 participants. Therapeutic Advances in Chronic Disease, 13, 20406223221109454. https://doi.org/10.1177/20406223221109454
20. Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022). Metformin: A narrative review of its potential benefits for cardiovascular disease, cancer, and dementia. Pharmaceuticals (Basel), 15(3), 312. https://doi.org/10.3390/ph15030312
21. Xue, Y., & Xie, X. (2023). The association between metformin use and risk of developing severe dementia among AD patients with type 2 diabetes. Biomedicines, 11(11), 2935. https://doi.org/10.3390/biomedicines11112935

Most read articles by the same author(s)